Investigational Compound
A compound being evaluated in formal clinical trials under regulatory oversight but not yet approved. Investigational status indicates progression beyond preclinical research into human testing — a significant milestone requiring substantial safety evidence. PeptideTrace tracks investigational compounds as a distinct classification.
Technical Context
Investigational compound status indicates: formal IND application filed with regulatory authority, at least one clinical trial registered and conducted under regulatory oversight, defined protocol with ethics committee approval, and safety monitoring in place. This distinguishes investigational compounds from research compounds, which may have only preclinical data without regulatory involvement. PeptideTrace classifies 20 compounds as investigational — primarily in the weight management pipeline (next-generation GLP-1 RAs, triple agonists such as retatrutide, amylin analogues such as cagrilintide). The investigational classification may change as compounds advance (moving to 'approved' upon approval) or fail (potentially reclassified or removed). Key investigational endpoints (Phase II/III data) are tracked for these compounds as they progress toward potential regulatory submissions.